Targets for parathyroid hormone in secondary hyperparathyroidism: is a “one-size-fits-all” approach appropriate? A prospective incident cohort study

Table 3 Characteristics of dialysis subgroups identified at time of secondary hyperparathyroidism (SHPT) diagnosis: variables used to cluster dialysis patients at time of SHPT diagnosis

Variables	Group 1^a	Group 2^a	Group 3^a	Group 4^a
	(N = 113, 37.2%)	(N = 73, 24.0%)	(N = 75, 24.7%)	(N = 43, 14.1%)	p
Clinical signs, %
All clinical signs	64	55	56	54	0.512
Clinical signs reported in PAS^b	55	45	37	33	0.031
Biological parameters
PTH^c,d, ng/L	666 ± 182	630 ± 199	635 ± 233	449 ± 255	<0.0001
within KDIGO target, %	51	66	69	86	0.0004
Serum calcium^d, mg/L	89 ± 7	82 ± 6	89 ± 6	87 ± 7	<0.0001
Hypocalcemia, %	29	81	27	42	<0.0001
Serum phosphorus^d, mg/L	58 ± 17	62 ± 13	44 ± 12	52 ± 17	<0.0001
Hyperphosphatemia, %	81	96	25	67	<0.0001
Hypophosphatemia, %	4	4	0	2	<0.0001
Serum alkaline phosphatase^d, UI/L	100 ± 44	78 ± 29	120 ± 53	123 ± 99	<0.0001
Under median value, %	50	84	21	53	<0.0001
Treatments, %
Vitamin D and analogs	73	84	24	77	<0.0001
Calcium supplementation	68	95	35	86	<0.0001
Calcium-free phosphorus binders	58	93	25	65	<0.0001
Cinacalcet	0	0	3	98	<0.0001

^aGroup 1: “intermediate” patients, Group 2: younger patients with severe comorbidities, Group 3: elderly patients with few cardiovascular comorbidities, Group 4: patients who initiated cinacalcet; ^bParathyroidectomy Assessment of Symptoms questionnaire; ^cParathyroid hormone; ^dResults are presented as mean ± SD; p corresponds to ANOVA.

ISSN: 1471-2369